Why Halozyme, An IBD 50 Stock, Just Hit A Record High In Bullish Volume

Halozyme stock rocketed to a record high Friday as its newer Enhanze-tied products start driving incremental growth. Enhanze is a drug delivery platform that allows large volumes of intravenous meds to be given with an under-the-skin, or subcutaneous, shot. It does this by breaking down a key barrier in the skin. Despite a looming patent expiration in 2029, Leerink Partners…